Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/cg41
Introduction
|
This is a partial update of NICE clinical guideline 14 (published May 2004). The update has been developed by the National Collaborating Centre for Primary Care. The original guideline was also developed by the National Collaborating Centre for Primary Care. In this update, only the recommendations on magnetic resonance imaging (MRI) for breast cancer surveillance (section 1.4.4) have changed; minor amendments have been made elsewhere in this document, where necessary, to reflect these changes. These are highlighted in the document as 'NEW'. The original NICE guideline and supporting documents are available. |
This NICE guideline provides recommendations for the classification and care of women who are at a raised or high risk of developing hereditary breast cancer.
Breast cancer is the most common cancer in women. Most women with breast cancer do not have a family history of the disease, but it can be hereditary. Three genes have been identified that predispose women to breast cancer – BRCA1, BRCA2 and TP53.
The objective of this guideline is to decrease breast cancer morbidity and mortality by assessing hereditary risk in people before breast cancer develops and providing regular surveillance to identify breast cancer at an early stage.
This guideline makes recommendations on primary, secondary and tertiary care management of women at risk of hereditary or familial breast cancer.
This guideline does not address treatments for breast cancer once the disease has been diagnosed. It also does not address screening men for breast cancer, although this may be appropriate if the risk is sufficiently high. Patients who do not have a raised or high risk of familial breast cancer should be managed in line with current national breast screening guidance after the age of 50.